Microba Life Sciences (MAP) Stock Price, News & Analysis

Company Overview

Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, and Singapore. The company operates through two segments, Testing Services, and Research and Development. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; testing and data analysis services for personal and research testing; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases, as well as Databank for health and biome data. The company was incorporated in 2017 and is based in Brisbane, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$116.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: ASX:MAP
• CIK: N/A
• Web: microba.com
• Phone: 61 13 0097 4621
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$19.94 million
• Net Margins: -187.10%
• Pretax Margin: N/A
• Return on Equity: -55.15%
• Return on Assets: -30.76%

Debt

• Debt-to-Equity Ratio: 3.84
• Current Ratio: 2.61
• Quick Ratio: 6.50

Sales & Book Value

• Annual Sales: A$12.09 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.09 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 447,850,000
• Free Float: N/A
• Market Cap: A$116.44 million
• Optionable: Not Optionable
• Beta: 2.81